Cardiovascular complications of metastatic colorectal cancer treatment.
Colorectal cancer (CRC)
angiogenesis inhibitors
antimetabolites
cardiotoxicity
chemotherapy
tyrosine kinase inhibitors (TKIs)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
9
8
2019
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is the third most common malignancy in men and the second in women and the fourth cause of cancer death. Survival rates decrease greatly according to the stage of the disease at the time of diagnosis. Approximately 50% of CRC patients will develop metastatic disease (mCRC) with survival and prognosis depending on the timing of metastatic development, and the localization and number of metastatic sites. The overall survival of patients with mCRC has been significantly improved over the last years from approximately 12 to more than 30 months with the integration of multiple cytotoxic agents and targeted therapies. The optimal therapeutic strategy depends on the general condition and performance status of the patient, the resectability or not of metastases and the mutational status of the tumor in terms of
Identifiants
pubmed: 31392061
doi: 10.21037/jgo.2019.03.04
pii: jgo-10-04-797
pmc: PMC6657319
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
797-806Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Target Oncol. 2015 Mar;10(1):55-63
pubmed: 24599713
Eur J Surg Oncol. 2016 Sep;42(9):1337-42
pubmed: 27160353
Eur J Cancer. 2005 Jul;41(11):1542-6
pubmed: 15978800
Eur J Cancer. 2013 Aug;49(12):2633-42
pubmed: 23642329
Int J Colorectal Dis. 2015 Feb;30(2):205-12
pubmed: 25503801
Clin Drug Investig. 2014 Apr;34(4):231-40
pubmed: 24493142
Pharmacoeconomics. 2015 May;33(5):457-66
pubmed: 25616671
Laeknabladid. 2014 Feb;100(2):75-82
pubmed: 24639430
Drugs. 2015 Aug;75(12):1435-45
pubmed: 26220913
Clin Cancer Res. 2016 Sep 15;22(18):4545-9
pubmed: 27401247
Ann Oncol. 2014 May;25(5):1059-64
pubmed: 24558023
J Clin Oncol. 2015 Jun 1;33(16):1809-24
pubmed: 25918280
JAMA Surg. 2014 Jun;149(6):557-64
pubmed: 24718844
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer. 1993 Jan 15;71(2):493-509
pubmed: 8422644
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Am J Kidney Dis. 2007 Feb;49(2):186-93
pubmed: 17261421
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Therap Adv Gastroenterol. 2015 Sep;8(5):285-97
pubmed: 26327919
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Cancer. 2018 Jun 1;124(11):2337-2346
pubmed: 29579325
J Oncol Pharm Pract. 2012 Mar;18(1):132-5
pubmed: 21321041
BMJ Case Rep. 2017 May 22;2017:
pubmed: 28536214
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Int J Med Sci. 2018 Apr 3;15(7):659-665
pubmed: 29910669
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Pharmacotherapy. 2011 Feb;31(2):226
pubmed: 21275498
Expert Opin Drug Saf. 2009 Mar;8(2):191-202
pubmed: 19309247
JOP. 2009 Mar 09;10(2):215-20
pubmed: 19287123
Drugs R D. 2017 Mar;17(1):117-124
pubmed: 27848234
Expert Opin Pharmacother. 2005 Jun;6(7):1231-9
pubmed: 15957975
Br J Cancer. 2011 Feb 15;104(4):599-604
pubmed: 21304526
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Am J Emerg Med. 2012 Jan;30(1):257.e1-3
pubmed: 21208764
Anticancer Drugs. 2009 Jan;20(1):79-80
pubmed: 19353811
Ann Oncol. 2012 Jul;23(7):1672-9
pubmed: 22241897
Crit Rev Oncol Hematol. 2018 Apr;124:1-10
pubmed: 29548480
Curr Treat Options Cardiovasc Med. 2016 May;18(5):33
pubmed: 26932588
Cancer Med. 2016 Jul;5(7):1381-7
pubmed: 27109438
Can J Cardiol. 2014 May;30(5):534-43
pubmed: 24786444
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
pubmed: 17686822
Bull Cancer. 2006 Mar 1;93(3):E27-30
pubmed: 16567310
Eur J Cancer. 2017 May;76:93-99
pubmed: 28286287
Cochrane Database Syst Rev. 2000;(2):CD001216
pubmed: 10796760
Neth Heart J. 2009 Aug;17(7-8):277-80
pubmed: 19789694
J Med Econ. 2017 Jan;20(1):54-62
pubmed: 27603498
Clin Colorectal Cancer. 2015 Jun;14(2):72-80
pubmed: 25982297
Cancer Treat Rev. 2013 Dec;39(8):974-84
pubmed: 23582737
Drugs. 1999 Apr;57(4):475-84
pubmed: 10235688
Bull Cancer. 2018 Jul - Aug;105(7-8):707-719
pubmed: 29960638
J Am Heart Assoc. 2017 Aug 10;6(8):
pubmed: 28862931
World J Surg Oncol. 2013 Nov 28;11:306
pubmed: 24283603
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Oncol. 2009 Sep;20(9):1535-1542
pubmed: 19474115
Onco Targets Ther. 2017 Dec 28;11:123-129
pubmed: 29343971
Eur J Heart Fail. 2018 Dec;20(12):1732-1734
pubmed: 30328667
J Clin Oncol. 2011 May 1;29(13):1757-64
pubmed: 21422411
J Clin Oncol. 2011 Feb 20;29(6):603-6
pubmed: 21205751
Eur J Clin Pharmacol. 2014 Feb;70(2):225-31
pubmed: 24150533
BMC Cancer. 2016 Jul 04;16:386
pubmed: 27377645
Clin Colorectal Cancer. 2018 Sep;17(3):e457-e470
pubmed: 29605592
Medicine (Baltimore). 2017 Jan;96(3):e5946
pubmed: 28099361
Br J Cancer. 2017 Jan;116(3):389-397
pubmed: 28056465
Intern Med J. 2010 Apr;40(4):303-7
pubmed: 20529041
Recenti Prog Med. 2016 Apr;107(4):199-200
pubmed: 27093330
Clin Colorectal Cancer. 2018 Dec;17(4):e631-e637
pubmed: 29980490
Cardiooncology. 2015 Dec 7;1(1):6
pubmed: 33530150
Clin Cancer Res. 2012 May 1;18(9):2658-67
pubmed: 22421192